Reuters -- Bristol-Myers Squibb Co’s $2.4 billion acquisition of biotechnology company Medarex has not quenched its thirst for takeovers as it faces the 2011 patent expiration on Plavix, its biggest-selling drug, the company’s head of research and development said.
